
Clinical Trials Flowcharts

February 2026

Table of Contents

[Breast](#)

[GI](#)

[GU](#)

[Gynecologic](#)

[Head & Neck](#)

[Leukemia](#)

[Lymphoma](#)

[Melanoma](#)

[Myeloma](#)

[Neuroendocrine](#)

[Sarcoma](#)

[Thoracic](#)

[Cancer Services – Quad Cities](#)



To refer a patient:

To learn more about a specific trial, contact the MOG leader listed, or call the clinical trials hotline at 319-353-8155.

All calls to the clinical trials hotline will be returned within 48 hours.

The clinical trials team will then work with you to get your patient enrolled, when appropriate.

Iowa Clinical Trials Hotline

319-353-8155



Mimi McKay, MPH, BSN
Clinical Trial Navigator
marie-mckay@uiowa.edu

Breast Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEOADJUVANT TNBC


SCARLET: T2-T4, N0, M0 or T1-T3, N1-2, M0; no prior systemic therapy or radiation therapy with curative intent for current breast cancer

PI: Sneha Phadke

[NCT05929768](#)

BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only




BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only


ADJUVANT

ER+ /HER2-



BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

METASTATIC ER+/HER2-

LuMIERE:
 Progressed on ≥1 line of hormone-based therapy and ≤1 lines of cytotoxic chemotherapy (without hormone based therapy) for metastatic disease, measurable disease, can continue treatment up to 14 days of C1D1
PI: Yusuf Menda


NCT04939610

CO44657/PIONERA
 Locally advanced or metastatic;
 Resistance to adj ET (+CDKi): relapse on adj tx after 12 mo or off tx with TFI<12 mo; No prior systemic tx (1L)
 · *PI: Seema Harichand*

NCT06065748

BREAST CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only




Gastrointestinal Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155


PANCREATIC CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



PANCREATIC CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



COLORECTAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEOADJUVANT

Dostarlimab
 Criteria: Biopsy proven Stage II or III dMMR amenable to en bloc surgical resection; biopsy specimen has enough tissue for 4-6 FFPE slides; absence of metastatic disease

PI: Saima Sharif

NCT05239546

ADJUVANT

NRG-GI008
 Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

PI: Saima Sharif

NCT05174169


NSABP FC-13
 Criteria: Stage II/III colon, II/III rectal, or oligometastatic stage IV; no metastatic disease during screening; must have complete resection & at least 3 months of SOC chemo. Chemo/Rad is allowed; MSS or pMMR confirmed through CTDNA within 2 weeks of definitive all curative therapy

PI: Saima Sharif

NCT07058012

COLORECTAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



GASTRIC/GASTROESOPHAGEAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

1L

A022102
 Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease
 PI: Saima Sharif
 NCT05677490

METASTATIC

Astellas 8951-CL-0305
 Criteria: Advanced/metastatic/unresectable Gastric or GEJ; measurable disease; must be a candidate for mFOLFOX6 or CAPOX+Pembro; HER2-; CLDN18.2 in ≥ 75% of tumor cells; PD-L1+; MSI-high or mismatch deficient
 PI: Naomi Fei
 NCT06901531

Sanofi
 Criteria: Advanced/metastatic disease, Gastric/GEJ- failed or relapsed 1 prior line, no prior PD-1/PDL-1 allowed.
 PI: Saima Sharif
 NCT05584670

KQB168:
 Criteria: Gastric, GEJ, Esophageal; LA/Metastatic with no SOC options; PD on immunotherapy; measurable disease; previous brain mets allowed but must be stable; no active CNS or leptomeningeal; No prior PTPN inhibitors
 PI: Mohammed Milhem
 NCT06994806

HLX22-GC-301:
 Criteria: locally advanced or met GEJ/gastric with measurable disease; no prior tx for metastatic; HER2-positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH+ or FISH+
 PI: Christian Schultheis
 NCT06532006

Beamion BCGC-1:
 Documented HER2+ gastric, GEJ, or esophageal adenocarcinoma with presence of at least one RECIST measurable lesion
 PI: Sneha Phadke
 NCT06324357

TWINPEAK
 Criteria: 2L Locally advanced or metastatic GC/GEJ; measurable disease
 PI: Naomi Fei
 NCT05482893

BILIARY TRACT CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

Adjuvant

ARTEMIDE-Biliary01:
Criteria: Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1); randomization within 12 weeks after resection

PI: Naomi Fei

[NCT06109779](#)

HEPATOCELLULAR CARCINOMA

OPEN AT UIHC ONLY
 UIHC and Mission

PENDING
 Mission only

UNRESECTABLE

ROUTE90:

Criteria: Confirmed diagnosis of HCC, LIRADS 5 or biopsy; One lesion \geq 2 cm in diameter, no more than 3 lesions; Max 3 lesions and single lesion size \leq 8 cm & sum tumor dimensions of \leq 12 cm; Evidence that $>$ 33% of the total liver volume is disease-free; No extra hepatic disease

PI: Michael Hummel

[NCT05953337](#)

Genitourinary Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BLADDER CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NMIBC

Adapt
 Criteria: Histologically confirmed urothelial carcinoma of bladder (Ta, T1, or Tis) on TURBT; BCG unresponsive disease (persistent CIS with or without the presence of Ta or T1 tumors within 12 months of completion of BCG, or recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy)

PI: Michael O'Donnell

[NCT03317158](#)

NEOADJUVANT

<p>EA8192 Criteria: High grade upper tract urothelial carcinoma proven by biopsy with 12 weeks of randomization; no component of small cell/neuroendocrine carcinoma; no evidence of metastatic disease or enlarged LN</p> <p style="text-align: center;"><i>PI: Umar Farooq</i></p> <p style="text-align: center;">NCT04628767</p>	<p>V940-005 Criteria: muscle-invasive urothelial carcinoma</p> <p style="text-align: center;"><i>PI: Mohammed Milhem</i></p> <p style="text-align: center;">NCT06305767</p>
---	---

ADJUVANT


V940-005
 Criteria: muscle-invasive urothelial carcinoma; high-risk pathologic disease after radical resection

PI: Mohammed Milhem

[NCT06305767](#)

BLADDER CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



PROSTATE CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

METASTATIC HORMONE SENSITIVE

S1802
 Criteria: Adenocarcinoma of prostate; no prior local therapy for prostate adenocarcinoma; evidence of metastatic disease on bone scan and CT or MRI; received no more than 28 weeks of standard systemic therapy(SST); no progression while on SST; must have surgically resectable disease per urology consult

PI: Joseph Caster

[NCT03678025](#)

METASTATIC CRPC

S2210:
 Criteria: No distant mets; High or very high risk disease; cT3a-cT4x or Grade group 4 or 5 or PSA > 20 ng/mL; must have BRCA2 or 1 mutation;

PI: Fernando Barbosa Maciel

[NCT05806515](#)

A032102:
 Criteria: histologies including neuroendocrine, small cell and sarcomatoid prostate cancer are allowed; progressive mCRPC; must have received ARSI and taxane; patients selected to receive Lu177 must have PSMA

PI: Fernando Barbosa Maciel

[NCT06632977](#)

Alphabreak:
 Criteria: Open label, non-randomized. CrCl ≥ 60 mL/min, progressed after ≥2 of Pluvicto, no liver mets (phase 2), measurable disease

PI: Yusuf Menda
coPI: Kristin Plichta

[NCT06402331](#)

KIDNEY CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

LOCALLY ADVANCED/METASTATIC

2L+


KO-2806
Criteria: Histologically or cytologically confirmed advanced solid tumors; must have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype

PI: Doug Laux

[NCT06026410](#)

KIDNEY CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



Urothelial CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

METASTATIC

A031702:
Criteria:, urethra clear cell, SCC, Plasmacytoid, Other misc. variants, Urethra, bone only metastatic. Metastatic disease, received up to 2 systemic therapies or treatment naïve, no prior PDL1 or CTLA4, Small cell should have received prior platinum combo as neoadjuvant/adjuvant or first line

PI: Fernando Maciel Barbosa

NCT03866382

Penile CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

METASTATIC

A031702:
Criteria: Metastatic disease, received up to 2 systemic therapies or treatment naïve, no prior PDL1 or CTLA4

PI: Fernando Maciel Barbosa

NCT03866382

Gynecologic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

OVARIAN CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

LOW GRADE SEROUS CARCINOMA

NRG-GY019 :
 Criteria: Newly diagnosed, stage II-IV low-grade serous ovarian, fallopian tube and primary peritoneal cancers; must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (≤ 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) allowed; must enroll within 8 weeks of primary surgery

PI: David Bender

NCT04095364

HIGH GRADE SEROUS CARCINOMA

GOG-3078-GLORIOSA (Maintenance therapy):
 Criteria: Recurrent (1st recurrence), platinum-sensitive high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer; FR α -High; subjects who have not progressed after second-line platinum-based chemotherapy plus bevacizumab; prior PARP required if BRCA mutated; must be randomized within 8 weeks from last dose of platinum-based triplet therapy

PI: David Bender

NCT05445778


GOG-3086 REFRAme-01:
 Criteria: Recurrent, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer; FOLR1 expression $\geq 25\%$ on central lab screening IHC testing; measurable disease required; Up to 3 prior regimens – no prior FOLR1-targeting ADC; prior bevacizumab required unless contraindicated

PI: David Bender

NCT05870748

OVARIAN CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



ENDOMETRIAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEWLY DIAGNOSED HER2+

NRG-GY026 :
 Criteria: stage IA-IVB, non-recurrent, chemo-naive, HER2+ endometrial serous carcinoma or endometrial carcinosarcoma; must have myoinvasive disease; must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration; no prior radiation therapy, biologic, or targeted therapy for endometrial cancer
PI: David Bender

NCT05256225

RECURRENT dMMR

NRG-GY025:
 Criteria: Recurrent MMR-deficient endometrial cancer; serous and carcinosarcoma subtypes excluded; measurable or detectable disease required; patients may have received up to 2 prior lines of systemic therapy; prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings; must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition
PI: David Bender

NCT05112601

ENDOMETRIAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

METASTATIC

NRG-GY028
 Criteria:
 Recurrent/metastatic grade 1 or 2 endometrioid endometrial cancer; measurable disease required; may have received unlimited prior lines of therapy; prior hormonal therapy (e.g., megestrol acetate, medroxyprogesterone acetate, aromatase inhibitor, tamoxifen, fulvestrant) it must have completed at least 6 months prior to registration; no prior AKT inhibitor

PI: David Bender

NCT05538897

ACR-368-201
 Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen

PI: Emily Hill

NCT05548296


IMC-F106C-101:
 Criteria:
 HLA-A*02:01 positive; PRAME positive tumor; Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies

PI: Margaret Byrne

NCT04262466

CERVICAL CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



GERM CELL TUMOR

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

LOW OR STANDARD RISK

AGCT1531 :
 Criteria: Low risk stage I immature teratoma (IT);
 site: ovarian; tumor markers:
 alpha-FP =< 1,000 ng/mL,
 beta-HCG institutional
 normal; all ages
Standard risk 2 (SR2)
 Site: ovarian; stage: COG
 stage II and III, FIGO stage IC,
 II and III; histology: must
 contain at least one of the
 following: yolk sac tumor,
 embryonal carcinoma, or
 choriocarcinoma; age < 25

PI: David Dickens

NCT03067181

INTERMEDIATE OR POOR RISK

AGCT1532:
 Criteria: Histologically or
 cytologically confirmed germ
 cell; or Exceptionally raised
 tumour markers (AFP ≥
 1000ng/mL and/or HCG ≥ 5000
 IU/L) without histologic or
 cytologic confirmation in the rare
 case where pattern of
 metastases consistent with GCT,
 high tumour burden, and a need
 to start therapy urgently; Primary
 arising in testis, ovary, retro-
 peritoneum, or mediastinum;
 Intermediate or poor prognosis
 as defined by IGCCC
 classification³

PI: David Dickens

NCT02582697

BRCA1 OVARIAN CANCER RISK REDUCTION

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

INTERMEDIATE OR POOR RISK

NRG-CC008:
Criteria: Individuals 35-50 years of age, inclusive; positive CLIA-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient; non-randomized prospective trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers; patient choice of bilateral salpingectomy or bilateral salpingo-oophorectomy (with or without hysterectomy); no prior radiation to the abdomen/pelvis; no prior hormonal therapy within 90 days *PI: David Bender*

NCT04251052

Head and Neck Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

HEAD AND NECK CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

HNSCC

ADJUVANT


GSK-221530 JADE:
Has newly diagnosed unresected LA histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy with curative intent and has no evidence of distant metastatic disease.

PI: Doug Laux

[NCT06256588](#)

HEAD AND NECK CANCER


<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



HEAD AND NECK CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

METASTATIC HNSCC



HEAD AND NECK CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

NASOPHARYNGEAL

Study to Evaluate BL-B01D1: Has measurable disease; LVEF $\geq 50\%$; must have received platinum and PD1

PI: Sneha Phadke

NCT05983432

HEAD AND NECK CANCER

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

THYROID CANCER

EA3231:
Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

[NCT06475989](#)

NON-MELANOMA SKIN CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

CUTANEOUS SQUAMOUS CELL

1L

COMBINE-EGFR-1: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

PI: Doug Laux

NCT04626635

MERKEL, BASAL, SCC

Replimune IGNYTE
 Criteria: Locally advanced or metastatic NMSC not considered treatable by surgery; must have received 8 wks of anti-PD1/PDL1 as their last line of therapy and progressed while on treatment

PI: Doug Laux

NCT: 03767348

MERKEL CELL

HCRN MCC20-443
 Criteria: Histological or cytological evidence of Merkel cell cancer per AJCC, 8th ed; presence of somatostatin receptors by Ga-68 dotatate imaging; progress on treatment with anti-PD1/L1 administered either as monotherapy or in combination with other check point inhibitors or other therapies

PI: Doug Laux

NCT: 05583708


Leukemia Clinical Trials

Clinical Trials Hotline: 319-353-8155

ACUTE MYELOID LEUKEMIA (AML)


<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEWLY DIAGNOSED



ACUTE MYELOID LEUKEMIA (AML)

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



MALIGNANT HEME (OTHER)

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEWLY DIAGNOSED MDS

SY-1425-301
 Criteria: Must be RARA-positive based on investigational assay; diagnosis of MDS according to WHO classification and classified as very high, high, or intermediate risk per IPSS

PI: Grek Sutamtewagul

NCT: 04797780

ANY MYELOID MALIGNANCY

CA055-001
 Criteria: Moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria

PI: Grek Sutamtewagul


NCT: 05209295

Lymphoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

LARGE CELL LYMPHOMAS


<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



LARGE CELL LYMPHOMAS


<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

RELAPSED/REFRACTORY



LARGE CELL LYMPHOMAS

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



MANTLE CELL LYMPHOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

FRONTLINE

A052101:

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients (Age ≥ 70 or ≥ 60 with selected comorbidities) with Mantle Cell Lymphoma

PI: Umar Farooq


[NCT: 05976763](#)

RELAPSED/REFRACTORY

<p>ELM-2</p> <p>A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated</p> <p style="text-align: right;"><i>PI: Umar Farooq</i></p> <p style="text-align: center;">NCT: 03888105</p>	<p>BGB-16673</p> <p>A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies</p> <p style="text-align: right;"><i>PI: Eric Mou</i></p> <p style="text-align: center;">NCT: 05006716</p>	<p>BGB-11417-302</p> <p>A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma</p> <p style="text-align: right;"><i>PI: Tara Graff</i></p>
---	--	--


FOLLICULAR LYMPHOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



FOLLICULAR LYMPHOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



CLL/SLL

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

FRONTLINE

MK-1026-011
BELLWAVE:

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PI: Eric Mou

[NCT06136559](#)

RELAPSED/REFRACTORY

Lily J2N-MC-JZNX
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor

PI: Tara Graff

[NCT06588478](#)

BGB-16673

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou

[NCT: 05006716](#)

CLASSICAL HODGKIN LYMPHOMA

<input type="checkbox"/> OPEN AT UIHC ONLY	<input type="checkbox"/> PENDING
<input type="checkbox"/> UIHC and Mission	<input type="checkbox"/> Mission only

FRONTLINE

AHOD2131:
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

PI: David Dickens

NCT05675410

RELAPSED/REFRACTORY

BTCRC HEM 15-027:
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

PI: Umar Farooq

NCT03681561

T-CELL LYMPHOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

FRONTLINE

A051902:

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative (<10%) Peripheral T-Cell Lymphomas

PI: Umar Farooq

NCT: 04803201

ADJUVANT

EA423:

Testing High-Dose Chemo & Stem Cell Infusion to Improve Survival in T-cell Lymphoma Patients

PI: Eric Mou


NCT06724237

RELAPSED/REFRACTORY

<p>CPI-818-004:</p> <p>PTCL-NOS, FHTCLs or sALCL; Progressed or relapsed/refractory to SOC. At least 1 but no more than 3 prior lines. FDG avid disease or at least 1.5 cm</p> <p><i>PI: Eric Mou</i></p> <p>NCT06561048</p>	<p>MB-105:</p> <p>A single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).</p> <p><i>PI: Eric Mou</i></p> <p>NCT06534060</p>
--	---

OTHER LYMPHOMAS

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only




Melanoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

CUTANEOUS MELANOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



UVEAL MELANOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

1L

IDE196-001
 Criteria: Metastatic disease may be treatment naïve or have progressed on or after most recent therapy.

PI: Mohammed Milhem

[NCT03947385](#)

Relapsed/Refractory

IDE196-001
 Criteria: Metastatic disease may be treatment naïve or have progressed on or after most recent therapy.

PI: Mohammed Milhem

[NCT03947385](#)

Checkpoint Inhibitor Naïve

RP2-202
 Criteria: Disease not amenable to surgical resection; at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for LN); willing to provide tumor biopsy samples

PI: Mohammed Milhem

[NCT06581406](#)

Myeloma Clinical Trials

Clinical Trials Hotline: 319-353-8155

MULTIPLE MYELOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

NEWLY DIAGNOSED

CARTITUDE-6
Phase 3
DVRd->Cilta-cel vs DVRd->auto stem cell in first line

No prior treatment for MM
ASCT is part of intended treatment plan

PI: Christopher Strouse

[NCT05257083](#)

MajesTEC-7
Phase 3 ; no prior treatment and either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

PI: Tara Graff

[NCT05552222](#)

S2209
Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance

1 cycle of non-daratumumab allowed prior to enrollment

Myeloma Frailty Score= frail or intermediate risk regardless of age

PI: Hira Shaikh

[NCT05561387](#)

MM 195 - FASTER
Phase 2 ; eligible for ASCT, measurable disease, must have at least PR on induction therapy without prior PD; prior completion of SOC mobilization and stem cell collection without use of chemo mobilization

PI: Christopher Strouse

[NCT06974786](#)

AMMbition
Phase 2 evaluation of combination of Dara-VRd + bispecific antibody + Cilta-cel in limited duration regimen

1 cycle of Dara-VRd permitted prior to enrollment


Standard risk MM

PI: Christopher Strouse

[NCT06577025](#)

MULTIPLE MYELOMA (CONT'D)

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



MULTIPLE MYELOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx
for high risk smoldering
myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

"High Risk" SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved
Dx in last 1 year, no myeloma defining criteria
PI: Christopher Strouse


[NCT: 03937635](#)

Neuro Oncology Clinical Trials

Clinical Trials Hotline: 319-353-8155

NEURO CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only




Neuroendocrine Clinical Trials

Clinical Trials Hotline: 319-353-8155

NEUROENDOCRINE CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only




Sarcoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

SARCOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only



SARCOMA

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

ANGIOSARCOMA

IGNYTE
 Criteria: locally advanced or metastatic disease; at least 1 measurable and injectable lesion; must have received 8 weeks of anti-PD1 as last line of therapy and progressed while on treatment

PI: Doug Laux

[NCT: 03767348](#)



CHONDROSARCOMA

<p>CHONQUER Criteria: LA/metastatic chondrosarcoma grades 1, 2, 3, not eligible for a curative resection; have received 0-1 prior systemic treatments in LA/metastatic setting</p> <p><i>PI: John Rieth</i></p> <p>NCT06127407</p>	<p>INBRX-109 Criteria: Conventional chondrosarcoma, unresectable or metastatic (clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma are not eligible)</p> <p><i>PI: Mohammed Milhem</i></p> <p>NCT: 04950075</p>
--	---



Thoracic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

NON-SMALL CELL LUNG CANCER




NON-SMALL CELL LUNG CANCER



NON-SMALL CELL LUNG CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

METASTATIC 3RD LINE+



SMALL CELL LUNG CANCER

<input type="checkbox"/>	OPEN AT UIHC ONLY	<input type="checkbox"/>	PENDING
<input type="checkbox"/>	UIHC and Mission	<input type="checkbox"/>	Mission only

1L

MOZART:
 Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules that are too extensive for radiation; No prior systemic therapy for small-cell lung cancer, with the following exceptions: Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study
PI: William Zeitler

[NCT05903092](#)

2ND LINE+

M23-385: Criteria: Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available
PI: William Zeitler

[NCT05599984](#)

Study to Evaluate BL-B01D1: Has measurable disease; LVEF ≥50%
PI: Sneha Phadke

[NCT05983432](#)

BTCRC-LUN20-462
 Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting
PI: William Zeitler

[NCT: 04919382](#)

Cancer Services – Quad Cities Clinical Trials

Clinical Trials Hotline: 319-353-8155

THORACIC CANCER

OPEN

PENDING

SCLC

BTCRC-LUN20-462

Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

PI: *William Zeitler*

[NCT: 04919382](#)

BREAST CANCER

OPEN

PENDING

TRIPLE NEGATIVE

SCARLET: T2-T4, N0, M0 or T1-T3, N1-2, M0; no prior systemic therapy or radiation therapy with curative intent for current breast cancer

PI: Sneha Phadke

[NCT05929768](#)

Optim-ICE: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization

PI: Sneha Phadke

[NCT05812807](#)

ER+

Cambria: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)

PI: Sneha Phadke

[NCT05774951](#)

ADE-MI: HR+HER2- who are prescribed abemaciclib

PI: Sneha Phadke

[NCT06169371](#)

BR009: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26

PI: Sneha Phadke

[NCT05879926](#)

HEAD AND NECK CANCER

OPEN

PENDING

THYROID CANCER

EA3231:

Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

[NCT06475989](#)

GI CANCER

OPEN PENDING

COLON

NRG-G1008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor \geq 12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing
PI: Saima Sharif

NCT: 05174169

GEJ

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif

NCT05677490

MULTIPLE MYELOMA

OPEN
 PENDING

SMOLDERING MYELOMA

Ecog-Acrin 173
 Phase 3 Pre-emptive tx
 for high risk smoldering
 myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

"High Risk" SMM = 2 of these:
 - >2.0 g/dl m-protein
 - Cyto: +1q, t[4;14], -17p, -13q
 - >20% PCs in marrow
 - Involved light chains 20x greater than uninvolved
 Dx in last 1 year, no myeloma defining criteria
PI: Christopher Strouse

NCT: 03937635

NEWLY DIAGNOSED

S2209
 Phase 3 evaluation
 comparing up front 3 drug regimens with single or double agent maintenance

No prior treatment for MM
 Myeloma Frailty Score= frail or intermediate risk regardless of age
PI: Hira Shaikh

NCT05561387